Formoterol Fumarate Patent Expiration
Formoterol Fumarate is Used for managing symptoms and improving lung function in individuals with chronic obstructive pulmonary disease. It was first introduced by Novartis Pharmaceuticals Corp
Formoterol Fumarate Patents
Given below is the list of patents protecting Formoterol Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Perforomist | US6667344 | Bronchodilating compositions and methods |
Jun 22, 2021
(Expired) | Viatris Specialty |
| Perforomist | US6814953 | Bronchodilating compositions and methods |
Jun 22, 2021
(Expired) | Viatris Specialty |
| Perforomist | US7348362 | Bronchodilating β-agonist compositions and methods |
Jun 22, 2021
(Expired) | Viatris Specialty |
| Perforomist | US7462645 | Bronchodilating beta-agonist compositions and methods |
Jun 22, 2021
(Expired) | Viatris Specialty |
| Perforomist | US8623922 | Bronchodilating Beta-agonist compositions and methods |
Jun 22, 2021
(Expired) | Viatris Specialty |
| Perforomist | US9730890 | Bronchodilating beta-agonist compositions and methods |
Jun 22, 2021
(Expired) | Viatris Specialty |
| Foradil | US6887459 | Aerosol composition comprising formoterol |
Nov 28, 2020
(Expired) | Novartis |
| Foradil | US6488027 | Powder inhaler |
Mar 08, 2019
(Expired) | Novartis |
Formoterol Fumarate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Formoterol Fumarate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists | Chiesi Farmaceutici S.p.A. | NA |
RECRUITING
(Jul 1, 2026)
| PHASE3 |
| Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD | Chiesi Farmaceutici S.p.A. | NA |
COMPLETED
(Jun 1, 2026)
| PHASE3 |
| Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma. | Chiesi Farmaceutici S.p.A. | NA |
COMPLETED
(Jun 1, 2026)
| PHASE3 |
| Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma | Chiesi Farmaceutici S.p.A. | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2 |
| TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER) | Chiesi Farmaceutici S.p.A. | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |